Aug 25, 2026 earnings call — Record quarter and planned CEO retirement
Net revenue for the fourth quarter was a record $19.4 million, up 12% versus the fourth quarter of last year.
Revenue $0.0B (est $0.0B) · EPS $0.39 (est $0.32)
Key quotes
"To address this, we initiated our triple down on bronchiectasis campaign last year to raise awareness of our therapy to highlight the integral part airway clearance plays in the treatment of bronchiectasis."
"The annualized home care revenue per weighted average direct sales representative in fiscal year 2026 was $1,145,000, exceeding Electromed's target range of $1 million to $1,100,000 per rep."
"Q4 marks our 15th consecutive quarter of year-over-year revenue and profit growth, a track record that reflects the durability of our direct-to-patient model and the growing recognition of SmartVest within the bronchiectasis community."
Analyst Q&A 3
sales hires and cash plans
Q (Kyle Bauser · Titan Partners): They asked about expectations for operating leverage in fiscal 2027 and whether the company will add more sales reps. They also asked how management plans to deploy the growing cash balance.
A: Management expects double-digit top-line growth and operating leverage in fiscal 2027, though not necessarily a repeat of last year. They ended the year with 64 direct sales reps and plan to have 67 territories filled this year, including 2 hospital account liaisons; some new reps will take time to ramp. On capital allocation, priorities are derisking, reinvesting in the business (support for reps, marketing, R&D) and opportunistic share repurchases.
"So as you heard in the prepared remarks, we really ended the year with 64 direct sales reps." — James Cunniff (CEO)
R&D focus and acquisitions
Q (Arailym Kanatkyzy · Freedom Broker): She asked what the higher R&D spend is funding—sustaining work, connectivity/smart nodes, or something adjacent like new vest sizes. She also asked what kinds of acquisitions the company would pursue.
A: R&D is a small base and is split between sustaining engineering (upgrading current technology) and innovation. Key R&D focuses are connectivity work and expanding the vest line, especially smaller sizes. On acquisitions, they are open to deals that add a complementary product for sales reps or that leverage their reimbursement and contracting capabilities.
"There's really 2 areas, one of which is connectivity and we're working on that right now, as you had mentioned." — James Cunniff (CEO)
insurance mix and new care guidelines
Q (Benjamin Haynor · Lake Street): He asked how to think about payer mix entering fiscal 2027 (commercial versus Medicare) and whether any trend exists. He also asked how the new CHEST guidelines affect reps' clinical detailing.
A: They do not see payer type during clinic visits; it is a 'black box' until a prescription is written. Historically the Medicare to commercial split has been about 50-50, and they added 6 million covered lives last fiscal year which reduces out-of-network issues. The CHEST guidelines will be published later this quarter, they include airway clearance, and a new bronchiectasis care pathway was also introduced to help providers.
"Really what the guidelines point to is what are some of the different things that a provider can use to take care of bronchiectasis patients." — James Cunniff (CEO)